BioWorld

Oct. 5, 2009

View Archived Issues

AIDSVax Results Likely Not Enough to Rescue VaxGen

Orexigen's New Empatic Data: Nice Obesity-Partner Package

Money Raised By Biotech in 2009: Jan 1 – Oct 1, 2009

Week in Review

Word on the Street

Public Financing Of Biotechnology: September 2009

BioTech Money Raised By Month in 2009: January – September

Other Financings Of Public Biotechnology Companies: September 2009

Venture Capital And Other Investments In Private Biotechnology Companies: September 2009

Milestone Payments From Corporate Partners: September 2009

Stock Indexes

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Recent Data May Resurrect Both AIDSVax and HIV Field

News that an HIV vaccine actually worked could resurrect AIDSVax, a product most folks left for dead in 2003, while breathing new life into the HIV vaccine field. Read More

Money Raised Year to Date

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...